If enacted, H1142 would amend several chapters of the Massachusetts General Laws to mandate that health insurance providers cover opioid antagonists like naloxone without cost-sharing. This change is intended to facilitate easier access to these medications by eliminating financial barriers for individuals who require them. The bill further stipulates that a prescription will not be necessary for obtaining naloxone, thereby promoting accessibility through a statewide standing order.
Summary
House Bill 1142, introduced by Representative Jon Santiago, proposes to prohibit cost-sharing for naloxone and other opioid antagonists, which are crucial in reversing opioid overdoses. The bill aims to ensure that coverage for these life-saving medications is provided without any out-of-pocket expenses for patients under various insurance plans, including those governed by the Massachusetts Group Insurance Commission. Naloxone is a vital component in addressing the state’s ongoing opioid crisis, and making it more accessible is a key strategy for public health.
Contention
There may be notable points of contention regarding the potential financial implications for insurance providers, as the prohibition of cost-sharing could affect the pricing structures that insurers have in place. Proponents argue that the bill significantly enhances public health measures, particularly in combating opioid overdoses, while opponents may raise concerns about the economic feasibility of requiring insurers to absorb these costs without any patient contributions. The balance between public health initiatives and insurance affordability could lead to discussions on the long-term sustainability of these provisions.
Health: pharmaceuticals; distribution of naloxone under the administration of opioid antagonist act to any individual; provide for. Amends title & secs. 103 & 107 of 2019 PA 39 (MCL 15.673 & 15.677) & adds sec. 106.